Pancreatic cancer resists treatment in part because the tumor is wrapped in a dense protective tissue, and in that quiet surrounding world a molecule called CD44 helps hold the defenses in place. Researchers at the Karlsruhe Institute of Technology have shown that when this molecule is switched off in the fibroblasts that build the shell, the walls loosen and the immune system can begin to reach the tumor. The findings, so far seen only in mice and cells grown in the laboratory, offer a glimpse of a gentler path: not tearing down the tissue around cancer, but teaching it to stop shielding the
CD44 Emerges as a Molecular Target for Reprogramming Pancreatic Tumor Fibroblasts
Changed, not destroyed: reprogramming the cells that shield pancreatic tumors
Mark
Why does this study stand out from other pancreatic cancer research?
Mimi
It targets the tissue around the tumor rather than the cancer cells. That surrounding tissue can make up as much as 90 percent of the tumor mass.
Mark
And CD44 is the lever?
Mimi
It's a molecule on cancer-associated fibroblasts that amplifies the signals activating them. When the team inactivated it, the fibroblasts made less matrix, released fewer cytokines and stopped suppressing immune cells.
Luke
What was the actual evidence for tumor shrinkage, though?
Mimi
Tumors got significantly smaller in a mouse model. That's the extent of the in vivo result described.
Luke
So no patient data at all.
Mimi
Right. Human cells were used in the lab, but nothing has been tested in people. The work is preclinical.
Mark
Orian-Rousseau stressed changing fibroblasts rather than destroying them. Why?
Mimi
Her point is that reprogramming opens the way to more effective and less disruptive treatments than killing the cells.
Luke
That's her view of the prospects, not a demonstrated outcome. How a CD44-blocking therapy would be delivered, or how safe it would be, isn't addressed in what's reported.
El Pulso
- Pancreatic tumors hide behind a thick, scar-like tissue wall that blunts the body's immune attack and frustrates many immunotherapies.
- Cancer-associated fibroblasts, the cells building that wall, are shown to rely on CD44 to amplify the signals that keep them suppressing immunity.
- Switching off CD44 in mouse models and human cells cut matrix production and immune suppression, letting immune cells strike the tumor more effectively.
- Tumor size fell significantly in mice, and the work now moves toward asking whether this fibroblast reprogramming can become a real therapy beyond the lab.
Pancreatic cancer resists treatment in part because the tumor is wrapped in a dense protective tissue, and in that quiet surrounding world a molecule called CD44 helps hold the defenses in place. Researchers at the Karlsruhe Institute of Technology have shown that when this molecule is switched off in the fibroblasts that build the shell, the walls loosen and the immune system can begin to reach the tumor. The findings, so far seen only in mice and cells grown in the laboratory, offer a glimpse of a gentler path: not tearing down the tissue around cancer, but teaching it to stop shielding the disease.
Pancreatic cancer is notoriously hard to treat, and part of the reason is the tissue that surrounds it. A dense layer wraps the tumor, shielding it and muting the body's immune response. Researchers at the Karlsruhe Institute of Technology in Germany have now found a molecular switch that helps maintain that protective environment.
The molecule is CD44, which sits on cancer-associated fibroblasts, the connective tissue cells that surround the tumor and help it grow, spread and evade immune defenses. In pancreatic cancer, this surrounding tissue can make up as much as 90 percent of the tumor's mass, which may help explain why immunotherapies that work elsewhere often fail here.
When the team inactivated CD44 in a mouse model and in human cells, the fibroblasts changed markedly. They produced less extracellular matrix, released fewer signaling cytokines and lost their ability to suppress immunity. With that brake released, immune cells attacked the tumor more effectively, and tumor size fell significantly in the mice.
Professor Véronique Orian-Rousseau, who leads the research group, stressed that the approach reprograms fibroblasts rather than destroying them, which may point toward therapies that are both more effective and less disruptive. The work is still preclinical, so the open question is whether this can be translated into treatment for patients.
Pancreatic cancer is among the hardest cancers to treat, and part of the reason lies not in the cancer cells themselves but in what surrounds them. A dense layer of tissue wraps the tumor, shielding it and dampening the body's immune response. Researchers at the Karlsruhe Institute of Technology (KIT) in Germany have now identified a molecular switch that helps govern that protective environment.
The molecule at the center of the work is CD44. It sits on cancer-associated fibroblasts, or CAFs, which are mutated connective tissue cells that surround the tumor. The findings were published in Cell Death & Disease under the DOI 10.1038/s41419-026-09155-5.
The background matters here. A tumor is not just a clump of malignant cells. It is embedded in a tumor microenvironment made up of supporting cells, blood vessels and immune cells. In pancreatic cancer, that surrounding tissue can account for up to 90 percent of the tumor's mass. CAFs are especially important within it. They encourage the tumor to grow and spread by building a scar-like tissue structure around it, and they suppress the body's own immune defenses. That is one explanation for why many immunotherapies that work against other cancers often fail in the pancreas.
The KIT team focused on what CD44 does inside these fibroblasts. They found that it amplifies key signals that activate the cells. To test what would happen without it, they inactivated CD44 in a mouse model and in human cells in the laboratory.
The fibroblasts changed markedly. According to Professor Véronique Orian-Rousseau, who heads the Cancer Cell Plasticity, Tumor Microenvironment and Metastasis research group at KIT's Institute of Biological and Chemical Systems - Functional Molecular Systems, the cells produced less extracellular matrix, released fewer cytokines and lost their ability to suppress the immune system. With that brake removed, immune cells were able to attack the tumor cells more effectively, and tumor size fell significantly in the mouse model.
Orian-Rousseau emphasized that the approach alters fibroblasts in a targeted way rather than destroying them. She said this opens up prospects for cancer treatments that are more effective and less disruptive.
The work remains preclinical, with results from mice and cultured human cells rather than patients. What to watch is whether blocking CD44 in fibroblasts can be turned into a therapy that holds up beyond the laboratory, and whether reprogramming the tumor's surroundings can make immunotherapy useful in pancreatic cancer.
Citas Notables
Changing fibroblasts in a targeted way by inactivating CD44, rather than destroying them, opens up new prospects for more effective and less disruptive cancer treatments.— Professor Véronique Orian-Rousseau, KIT
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine